Clorox (CLX) PT Lowered to $145 at Jefferies

Jefferies analyst Kaumil Gajrawala lowered the price target on Clorox (NYSE: CLX) to $145.00 (from $167.00) while maintaining a Buy rating.

The analyst comments "The next two quarters will be complicated to model. Shipping timing ahead of Clorox's US ERP rollout and wind down will create operating leverage and deleverage that surprises. We expect Clorox to guide to -4% to -2% organic sales and a low-teens% EPS decline for F26. We think consensus estimates need a recalibration (numbers are too high). The opportunity is in the messiness. Reit Buy, PT to $145."

You May Also Be Interested In

• Vera Therapeutics (VERA) PT Lowered to $80 at Goldman Sachs
• Macquarie Upgrades Hankook Tire Co Ltd (161390:KS) to Outperform
• Capstone Energy+, Inc. (CEPL) Reports Q2 Loss of $0.03